SG10201912394VA - Improved nanoparticle delivery systems - Google Patents

Improved nanoparticle delivery systems

Info

Publication number
SG10201912394VA
SG10201912394VA SG10201912394VA SG10201912394VA SG10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA
Authority
SG
Singapore
Prior art keywords
delivery systems
nanoparticle delivery
improved nanoparticle
improved
systems
Prior art date
Application number
SG10201912394VA
Inventor
Leon Wan
Winnie Lui
Paul Tardi
Lawrence Mayer
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of SG10201912394VA publication Critical patent/SG10201912394VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201912394VA 2015-07-15 2016-07-14 Improved nanoparticle delivery systems SG10201912394VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US201562252396P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
SG10201912394VA true SG10201912394VA (en) 2020-02-27

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912394VA SG10201912394VA (en) 2015-07-15 2016-07-14 Improved nanoparticle delivery systems

Country Status (17)

Country Link
US (3) US10285951B2 (en)
EP (1) EP3322404A4 (en)
JP (2) JP2018521068A (en)
KR (1) KR20180029242A (en)
CN (1) CN107920985B (en)
AU (2) AU2016294617B2 (en)
BR (1) BR112018000217A2 (en)
CA (1) CA2991062C (en)
CO (1) CO2018000146A2 (en)
HK (1) HK1251159A1 (en)
IL (1) IL256797B (en)
MA (1) MA42458A (en)
MX (1) MX2018000611A (en)
RU (1) RU2018105494A (en)
SG (1) SG10201912394VA (en)
WO (1) WO2017011685A1 (en)
ZA (1) ZA201800130B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218619A (en) * 2017-11-20 2021-01-12 西奈山伊坎医学院 Suppression of acclimatized immunity by therapeutic nanobiological formulation compositions
WO2019178443A1 (en) * 2018-03-16 2019-09-19 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
KR102088663B1 (en) * 2018-03-20 2020-03-13 한국세라믹기술원 Thermosponge nanoparticle platform for co-delivery of hydrophilic and hydrophobic drugs and its use
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
EP4013444A4 (en) * 2019-08-13 2023-11-01 Peptinovo Biopharma Inc. Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer
CN117355298A (en) 2021-03-19 2024-01-05 生物治疗探索股份有限公司 Compounds for modulating training immunity and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002331480B2 (en) * 2001-10-03 2007-10-25 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP2005518354A (en) * 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド Pharmaceutical composition containing a codrug
AU2003223226A1 (en) * 2003-02-20 2004-09-17 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
JP2008506780A (en) 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク. Particulate constructs for active agent release
AU2006235538A1 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
JP5537753B2 (en) * 2007-11-28 2014-07-02 セレーター ファーマスーティカルズ、インク. Improved taxane delivery system
WO2010117668A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2605797A2 (en) * 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
JP2013543008A (en) * 2010-11-19 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド Treatment method with BRAF inhibitor
CA3182519A1 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (en) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Chair with rocking mechanism
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
WO2017011685A1 (en) 2017-01-19
CA2991062C (en) 2023-06-20
EP3322404A4 (en) 2019-03-20
EP3322404A1 (en) 2018-05-23
US11413253B2 (en) 2022-08-16
JP2018521068A (en) 2018-08-02
CN107920985A (en) 2018-04-17
JP2022033751A (en) 2022-03-02
US10285951B2 (en) 2019-05-14
IL256797B (en) 2021-05-31
KR20180029242A (en) 2018-03-20
US20190209484A1 (en) 2019-07-11
AU2021286353A1 (en) 2022-01-20
HK1251159A1 (en) 2019-01-25
CA2991062A1 (en) 2017-01-19
BR112018000217A2 (en) 2018-09-04
MA42458A (en) 2018-05-23
MX2018000611A (en) 2018-09-06
US20180207104A1 (en) 2018-07-26
RU2018105494A (en) 2019-08-15
CO2018000146A2 (en) 2018-04-19
AU2016294617A1 (en) 2018-01-25
CN107920985B (en) 2022-03-01
US20210052508A1 (en) 2021-02-25
RU2018105494A3 (en) 2019-12-17
IL256797A (en) 2018-06-28
AU2016294617B2 (en) 2021-09-16
ZA201800130B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
HK1252464A1 (en) Aerosol delivery systems
GB201802837D0 (en) Awrosol delivery system
EP3212173A4 (en) Delivery systems
HK1249034A1 (en) Delivery vehicle
ZA201502203B (en) Nano particulate delivery system
EP3283752C0 (en) Fluid delivery system
HK1251159A1 (en) Improved nanoparticle delivery systems
HK1250370A1 (en) Bortezomib-based delivery system
GB201407614D0 (en) Content delivery system
GB201703170D0 (en) Improved goods delivery systems
GB201600229D0 (en) Fluid delivery system
GB201600232D0 (en) Fluid delivery system
GB201715590D0 (en) Delivery system
GB2559712B (en) Solid state delivery system
GB201420903D0 (en) Fluids delivery system
IL246874A0 (en) Drug delivery system
IL247106B (en) Substance delivery system
GB201509934D0 (en) Nanoparticles
GB201517654D0 (en) Object delivery system
GB201614126D0 (en) Delivery vehicle
GB2532245B (en) Cardioplegic agent delivery system
GB201721699D0 (en) Delivery system
GB201712561D0 (en) Delivery system
GB201522636D0 (en) Delivery system
IL248374A0 (en) Content delivery system